Biotree has completed a Series A financing of nearly 100 million CNY. Qiming Venture Partners led this round of funding.
The funds will primarily be used for platform expansion, R&D, production, and market promotion.
Biotree was founded in 2012 in Shanghai Fudan Science Park. It aims to conduct metabolomic and proteomic research on biological samples such as human bodies, animals, plants, and microorganisms and to translate the research findings into innovative products for clinical and general health screening and diagnosis.
Biotree is committed to becoming a leading testing and analysis institution by focusing on applying innovative mass spectrometry technology in the areas of life science and medical health. Biotree has established a complete platform integrating scientific research service, pharmaceutical enterprise service, clinical mass spectrometry service, and big data information service after ten years of development.
Biotree’s founding team includes members from well-known universities such as Fudan University and the Chinese Academy of Sciences, and the R&D team has members from top universities such as the University of Chinese Academy of Sciences, Fudan University, Shanghai Jiaotong University, Sichuan University, and the University of Texas Health Science Center.